Type 2 diabetes (T2DM) l Chronic kidney disease (CKD) l Cardiovascular disease (CVD)
TRANSFORMING HEALTH IN PENNSYLVANIA
Cardiovascular disease is the leading cause of death in Pennsylvania. The evidence demonstrating the interrelationships between chronic cardiometabolic diseases continues to expand, supporting a personalized approach to reducing risk.
- Early-stage metabolic dysfunction is often clinically silent
- Cardiometabolic diseases share risk factors including age, family history, health habits, and metabolic risk
- Patients with 1 chronic condition face increased risk of related conditions
Source: www.cdc.gov/nchs/pressroom/sosmap/heart_disease_mortality/heart_disease
Speak to a Quest representative and get ahead of chronic disease.
Get ahead of type 2 diabetes with the Insulin Resistance Panel with Score
For your patients with risk factors for diabetes, detecting insulin resistance now can help you work together to achieve better outcomes.
Insulin resistance can begin 10 years or more before type 2 diabetes is diagnosed1
Insulin resistance can progress to type 2 diabetes.2 The Insulin Resistance Panel with score identifies insulin resistance early, before fasting glucose and HbA1c become abnormal
Enhanced reporting gives you an effective counseling tool for patients who need to make lifestyle changes
Get ahead of Chronic Kidney Disease with the Kidney Profile with Enhanced Reporting
The majority of patients at risk for CKD are not receiving the recommended testing.3,4 Our Kidney Profile with enhanced reporting supports the National Kidney Foundation's (NKF) initiative to drive adoption of the profile for early detection of CKD. The Kidney Profile helps you:
Easily interpret results
Determine follow-up testing frequency
Identify risk earlier
Want to learn more? Check out our on-demand webinars.
IR Panel with Score Webinar
Detecting & Managing
Insulin Resistance
Learn what steps you can take to identify and manage insulin resistance in your patients
CKD Webinar
The Continuum of Chronic Kidney Disease Care: From Identification to Referral
Find out how early identification of risk can help you get ahead of chronic kidney disease.
References: 1. Holman, RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states, Diabetes Res Clin Pract. 1998;40 Suppl:S21-5. 2. Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018; 2:1050-1057. 3. National Kidney Foundation. Laboratory medicine impact on population health implementing the kidney profile. www.kidney.org/sites/default/files/02-11-8160_hbj_cmo_ascp_poster3.pdf. 4. National Kidney Foundation. CKDIntercept Laboratory Engagement Initiative. www.kidney.org/CKDintercept/laboratoryengagement